Mayne Pharma Acquires Rights to Generic Duragesic® Patch

Mayne Pharma has acquired the rights to the fentanyl transdermal delivery system (TDS), 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr from Par Pharmaceutical Inc. (Par).

This product was developed by Corium, a specialty pharmaceutical company focused on the development and manufacture of transdermal and transmucosal delivery systems.

Fentanyl TDS is an AB-rated generic equivalent to Duragesic®, indicated for the management of pain in opioid-tolerant patients severe enough to require daily treatment.  Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium, and acquired select inventory and the rights to market the product.  According to IMS Health, the annual market sales for the fentanyl patch were approximately $560 million for the 12 months ending  Dec. 31, 2016.

Mayne Pharma’s CEO Scott Richards said, "We are very pleased to have partnered with Corium on another complex and difficult-to-develop and manufacture product. The U.S. transdermal patch market is valued at more than $3.3 billion and is a well-regarded advanced drug delivery system that can better control drug release and can also lead to improved patient convenience and compliance.

"Mayne Pharma’s first marketed patch was Clonidine, indicated for the treatment of hypertension and one of Mayne Pharma’s top five generic products by sales. Our alliance with Corium now includes two marketed and one pipeline product that is currently filed with the U.S. Food and Drug Administration, and reinforces one of the key strategic benefits of the Teva portfolio acquisition to access a pipeline of new product opportunities through leveraging relationships with active pharmaceutical ingredient suppliers and contract development and manufacturing companies."